Pharvaris
Price & Volume
Stats
See more52W Range | $11.51-$25.49 |
Market Cap | $1B |
Shares Short | 557,715 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.81 |
News
See moreYahoo Finance • 27 days ago
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Yahoo Finance • last month
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
Yahoo Finance • 2 months ago
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Yahoo Finance • 2 months ago
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
About
CEO | Mr. Berndt Axel Edvard Modig CPA, M.B.A. |
CFO | Mr. David W. Nassif J.D. |
Address | Grafenauweg 8, Zug, Switzerland, 6300 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 108 |
